Login Register Cart 0
Generic placeholder image

Current Traditional Medicine

Editor-in-Chief

ISSN (Print): 2215-0838
ISSN (Online): 2215-0846

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nano-based Herbal Medicine: A New Candidate for Prostate Cancer Treatment?

Author(s): Tayebe Pouryousefi-koodehi, Mohammad Saeed Kahrizi, Hossein Roghani-Shahraki, Fatemeh Rezaei-Tazangi, Reza Arefnezhad* and Hossein Motedayyen*

Volume 10, Issue 7, 2024

Published on: 04 September, 2023

Article ID: e150823219728 Pages: 10

DOI: 10.2174/2215083810666230815142928

Price: $65

Abstract

Background: Prostate cancer (PCa) is known as the fifth reason for cancer-related deaths and involves a considerable population of men globally. In PCa, pluriform neoplasm with different cancer patterns is formed. Metastases have a substantial role in disease mortality, and lung, liver, and bone are among the common organs for metastasis. In spite of multiple attempts by researchers, it has not been recommended a safe and suitable approach against PCa so far.

Results: Fortunately, herbal remedies have opened a novel window in order to treat several cancers, such as PCa; however, there are some barriers regarding this curative method, like low bioavailability and absorption and low water solubility. On the contrary, some nano-based formulations have revealed a potential ability to overcome these limitations, and it seems that the co-use of herbal products and nanoformulations provides a good opportunity for treating PCa.

Conclusion: In this study, we argued about the therapeutic aspects of some nanoformulations of popular herbal products, such as curcumin, quercetin, and resveratrol, against PCa.

Graphical Abstract

[1]
Conteduca V, Mosca A, Brighi N, de Giorgi U, Rescigno P. New prognostic biomarkers in metastatic castration-resistant prostate cancer. Cells 2021; 10(1): 193.
[http://dx.doi.org/10.3390/cells10010193] [PMID: 33478015]
[2]
Nyk Ł, Tayara O, Ząbkowski T, Kryst P, Andrychowicz A, Malewski W. The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy. BMC Urol 2021; 21(1): 82.
[http://dx.doi.org/10.1186/s12894-021-00850-3] [PMID: 34006281]
[3]
Habib A, Jaffar G, Khalid MSZ, et al. Risk factors associated with prostate cancer. J Drug Deliv Ther 2021; 11(2): 188-93.
[http://dx.doi.org/10.22270/jddt.v11i2.4758]
[4]
Rodríguez Dorantes M. Prostate cancer spheroids: A three-dimensional model for studying tumor heterogeneity.In: Robles- Flores M, Ed Cancer Cell Signaling: Methods and Protocols. New York, NY: Springer US 2021; pp. 13-7.
[http://dx.doi.org/10.1007/978-1-0716-0759-6_2]
[5]
Guccini I, Revandkar A, D’Ambrosio M, et al. Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis. Cancer Cell 2021; 39(1): 68-82.e9.
[http://dx.doi.org/10.1016/j.ccell.2020.10.012] [PMID: 33186519]
[6]
Buckup M, Rice MA, Hsu EC, et al. Plectin is a regulator of prostate cancer growth and metastasis. Oncogene 2021; 40(3): 663-76.
[http://dx.doi.org/10.1038/s41388-020-01557-9] [PMID: 33219316]
[7]
Barsouk A, Padala SA, Vakiti A, et al. Epidemiology, staging and management of prostate cancer. Med Sci 2020; 8(3): 28.
[http://dx.doi.org/10.3390/medsci8030028] [PMID: 32698438]
[8]
Rocío O-R, Macarena L-L, Inmaculada S-B, et al. Compliance with the 2018 world cancer research fund/american institute for cancer research cancer prevention recommendations and prostate cancer. Nutrients 2020; 12(3): 768.
[http://dx.doi.org/10.3390/nu12030768] [PMID: 32183345]
[9]
Gibb J, Babawale O, Phan YC, Karim O. Dermatological manifestation of metastatic prostate cancer. BMJ Case Rep 2020; 13(11): e237115.
[http://dx.doi.org/10.1136/bcr-2020-237115] [PMID: 33257377]
[10]
Thienger P, Rubin MA. Prostate cancer hijacks the microenvironment. Nat Cell Biol 2021; 23(1): 3-5.
[http://dx.doi.org/10.1038/s41556-020-00616-3] [PMID: 33420486]
[11]
Ye F, Jiang S, Volshonok H, Wu J, Zhang DY. Molecular mechanism of anti-prostate cancer activity of Scutellaria baicalensis extract. Nutr Cancer 2007; 57(1): 100-10.
[http://dx.doi.org/10.1080/01635580701268352] [PMID: 17516867]
[12]
Ghosh S, Hazra J, Pal K, Nelson VK, Pal M. Prostate cancer: Therapeutic prospect with herbal medicine. Curr Res Pharmacol Drug Discov 2021; 2: 100034.
[http://dx.doi.org/10.1016/j.crphar.2021.100034] [PMID: 34909665]
[13]
Li S, Yu Y, Bian X, et al. Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling. Arch Toxicol 2021; 95(5): 1683-701.
[http://dx.doi.org/10.1007/s00204-021-03023-1] [PMID: 33713150]
[14]
Tian R, Liu X, Luo Y, et al. Apoptosis exerts a vital role in the treatment of colitis-associated cancer by herbal medicine. Front Pharmacol 2020; 11: 438.
[http://dx.doi.org/10.3389/fphar.2020.00438] [PMID: 32410986]
[15]
Mukherjee A, Paul M, Mukherjee S. Recent progress in the theranostics application of nanomedicine in lung cancer. Cancers 2019; 11(5): 597.
[http://dx.doi.org/10.3390/cancers11050597] [PMID: 31035440]
[16]
Lai WF, Tang R, Wong WT. Ionically crosslinked complex gels loaded with oleic acid-containing vesicles for transdermal drug delivery. Pharmaceutics 2020; 12(8): 725.
[http://dx.doi.org/10.3390/pharmaceutics12080725] [PMID: 32748814]
[17]
Mamillapalli V. Nanoparticles for herbal extracts. Asian J Pharm 2016; 10(2): 34-48.
[18]
Grynkiewicz G, Ślifirski P. Curcumin and curcuminoids in quest for medicinal status. Acta Biochim Pol 2012; 59(2): 201-12.
[http://dx.doi.org/10.18388/abp.2012_2139] [PMID: 22590694]
[19]
Zhang X, Ni L, Zhu Y, et al. Quercetin inhibited the formation of lipid oxidation products in thermally treated soybean oil by trapping intermediates. J Agric Food Chem 2021; 69(11): 3479-88.
[http://dx.doi.org/10.1021/acs.jafc.1c00046] [PMID: 33703898]
[20]
Liu Y, You Y, Lu J, Chen X, Yang Z. Recent advances in synthesis, bioactivity, and pharmacokinetics of pterostilbene, an important analog of resveratrol. Molecules 2020; 25(21): 5166.
[http://dx.doi.org/10.3390/molecules25215166] [PMID: 33171952]
[21]
Zhou X, Chen Q, Wang H, Zhang C, Fu B, Wang G. Specific expression of lncRNA RP13-650J16.1 and TCONS_00023979 in prostate cancer. Biosci Rep 2018; 38(5): BSR20171571.
[http://dx.doi.org/10.1042/BSR20171571] [PMID: 30279207]
[22]
Murray TB. The pathogenesis of prostate cancer. Exon Publications 2021; 29-41.
[http://dx.doi.org/10.36255/exonpublications.prostatecancer.pathogenesis.2021]
[23]
Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephrourol Mon 2013; 5(3): 792-800.
[http://dx.doi.org/10.5812/numonthly.9430] [PMID: 24282788]
[24]
Tang W, Wan S, Yang Z, Teschendorff AE, Zou Q. Tumor origin detection with tissue-specific miRNA and DNA methylation markers. Bioinformatics 2018; 34(3): 398-406.
[http://dx.doi.org/10.1093/bioinformatics/btx622] [PMID: 29028927]
[25]
Wen X, Zhou L, Wu X, et al. The PI3K AKT pathway in the pathogenesis of prostate cancer. Front Biosci 2016; 21(5): 1084-91.
[http://dx.doi.org/10.2741/4443] [PMID: 27100493]
[26]
Tindall DJ, Lonergan PE. Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011; 10(1): 20.
[http://dx.doi.org/10.4103/1477-3163.83937] [PMID: 21886458]
[27]
Haverkamp J, Charbonneau B, Ratliff TL. Prostate inflammation and its potential impact on prostate cancer: A current review. J Cell Biochem 2008; 103(5): 1344-53.
[http://dx.doi.org/10.1002/jcb.21536] [PMID: 17955503]
[28]
Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU Int 2014; 113(6): 986-92.
[http://dx.doi.org/10.1111/bju.12452] [PMID: 24053309]
[29]
Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci 2003; 100(5): 2645-50.
[http://dx.doi.org/10.1073/pnas.0437939100] [PMID: 12598651]
[30]
Kuniyasu H, Troncoso P, Johnston D, et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000; 6(6): 2295-308.
[PMID: 10873080]
[31]
Safari H, Zabihi E, Pouramir M, et al. Decrease of intracellular ROS by arbutin is associated with apoptosis induction and downregulation of IL‐1β and TNF‐α in LNCaP; prostate cancer. J Food Biochem 2020; 44(9): e13360.
[http://dx.doi.org/10.1111/jfbc.13360] [PMID: 32614483]
[32]
Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009; 282(2): 125-36.
[http://dx.doi.org/10.1016/j.canlet.2008.12.011] [PMID: 19185987]
[33]
Ashrafizadeh M, Zarrabi A, Hashemi F, et al. Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects. Life Sci 2020; 256: 117984.
[http://dx.doi.org/10.1016/j.lfs.2020.117984] [PMID: 32593707]
[34]
Roghani-Shahraki H, Karimian M, Valipour S, Behjati M, Arefnezhad R, Mousavi A. Herbal therapy as a promising approach for regulation on lipid profiles: A review of molecular aspects. J Cell Physiol 2021; 236(8): 5533-46.
[http://dx.doi.org/10.1002/jcp.30282] [PMID: 33469926]
[35]
Soliman WE, Shehata TM, Mohamed ME, Younis NS, Elsewedy HS. Enhancement of curcumin anti-inflammatory effect via formulation into myrrh oil-based nanoemulgel. Polymers 2021; 13(4): 577.
[http://dx.doi.org/10.3390/polym13040577] [PMID: 33672981]
[36]
Liu D, Chen Z. The effect of curcumin on breast cancer cells. J Breast Cancer 2013; 16(2): 133-7.
[http://dx.doi.org/10.4048/jbc.2013.16.2.133] [PMID: 23843843]
[37]
Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr 2010; 5(1): 61-74.
[http://dx.doi.org/10.1007/s12263-009-0152-3] [PMID: 19806380]
[38]
Chen HW, Lee JY, Huang JY, et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 2008; 68(18): 7428-38.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-6734] [PMID: 18794131]
[39]
Gao W, Yu-Wai Chan J, Ignance Wei W, Wong TS, et al. Anti-cancer effects of curcumin on head and neck cancers. Anti-Cancer Agen MedicinChemi 2012; 12(9): 1110-6.
[http://dx.doi.org/10.2174/187152012803529736]
[40]
Heidari S, Mahdiani S, Hashemi M, Kalalinia F. Recent advances in neurogenic and neuroprotective effects of curcumin through the induction of neural stem cells. Biotechnol Appl Biochem 2020; 67(3): bab.1891..
[http://dx.doi.org/10.1002/bab.1891] [PMID: 31978939]
[41]
Almatroodi SA, Syed MA, Rahmani AH. Potential therapeutic targets of curcumin, most abundant active compound of turmeric spice: Role in the management of various types of cancer. Recent Patents Anticancer Drug Discov 2021; 16(1): 3-29.
[http://dx.doi.org/10.2174/1574892815999201102214602] [PMID: 33143616]
[42]
Lu QY, Yang Y, Jin YS, et al. Effects of green tea extract on lung cancer A549 cells: Proteomic identification of proteins associated with cell migration. Proteomics 2009; 9(3): 757-67.
[http://dx.doi.org/10.1002/pmic.200800019] [PMID: 19137550]
[43]
Li H, Tan L, Zhang JW, et al. Quercetin is the active component of Yang-Yin-Qing-Fei-Tang to induce apoptosis in non-small cell lung cancer. Am J Chin Med 2019; 47(4): 879-93.
[http://dx.doi.org/10.1142/S0192415X19500460] [PMID: 31179723]
[44]
Flora G, Gupta D, Tiwari A. Nanocurcumin: A promising therapeutic advancement over native curcumin Crit reviews™ in therap drug carrier systems 2013; 30(4): 112-24.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2013007236]
[45]
Yallapu M, Ray Dobberpuhl M, Maher D, Jaggi M, Chauhan S. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab 2012; 13(1): 120-8.
[http://dx.doi.org/10.2174/138920012798356952] [PMID: 21892919]
[46]
Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20(52): 7597-609.
[http://dx.doi.org/10.1038/sj.onc.1204997] [PMID: 11753638]
[47]
Yallapu MM, Khan S, Maher DM, et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 2014; 35(30): 8635-48.
[http://dx.doi.org/10.1016/j.biomaterials.2014.06.040] [PMID: 25028336]
[48]
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012; 161(2): 505-22.
[http://dx.doi.org/10.1016/j.jconrel.2012.01.043] [PMID: 22353619]
[49]
Yallapu MM, Jaggi M, Chauhan SC. Poly(β-cyclodextrin)/curcumin self-assembly: A novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells. Macromol Biosci 2010; 10(10): 1141-51.
[http://dx.doi.org/10.1002/mabi.201000084] [PMID: 20572274]
[50]
Yallapu MM, Jaggi M, Chauhan SC. β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B Biointerfaces 2010; 79(1): 113-25.
[http://dx.doi.org/10.1016/j.colsurfb.2010.03.039] [PMID: 20456930]
[51]
Vellampatti S, Chandrasekaran G, Mitta SB, Lakshmanan VK, Park SH. Metallo-Curcumin-Conjugated DNA complexes induces preferential prostate cancer cells cytotoxicity and pause growth of bacterial cells. Sci Rep 2018; 8(1): 14929.
[http://dx.doi.org/10.1038/s41598-018-33369-z] [PMID: 30297802]
[52]
Guan Y, Zhou S, Zhang Y, et al. Therapeutic effects of curcumin nanoemulsions on prostate cancer. J Huazhong Univ Sci Technolog Med Sci 2017; 37(3): 371-8.
[http://dx.doi.org/10.1007/s11596-017-1742-8] [PMID: 28585133]
[53]
Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: Formation, properties and applications. Soft Matter 2016; 12(11): 2826-41.
[http://dx.doi.org/10.1039/C5SM02958A] [PMID: 26924445]
[54]
Bevacqua E, Curcio M, Saletta F, Vittorio O, Cirillo G, Tucci P. Dextran-curcumin nanosystems inhibit cell growth and migration regulating the epithelial to mesenchymal transition in prostate cancer cells. Int J Mol Sci 2021; 22(13): 7013.
[http://dx.doi.org/10.3390/ijms22137013] [PMID: 34209825]
[55]
Chen F, Huang G, Huang H. Preparation and application of dextran and its derivatives as carriers. Int J Biol Macromol 2020; 145: 827-34.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.11.151] [PMID: 31756474]
[56]
Shen MY, Liu TI, Yu TW, et al. Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/thermotherapy delivery system for local treatment of colon cancer. Biomaterials 2019; 197: 86-100.
[http://dx.doi.org/10.1016/j.biomaterials.2019.01.019] [PMID: 30641267]
[57]
Chen Y, Gao Y, Li Y, Wang K, Zhu J. Synergistic chemo-photodynamic therapy mediated by light-activated ROS-degradable nanocarriers. J Mater Chem B Mater Biol Med 2019; 7(3): 460-8.
[http://dx.doi.org/10.1039/C8TB03030H] [PMID: 32254733]
[58]
Tang SM, Deng XT, Zhou J, Li QP, Ge XX, Miao L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed Pharmacother 2020; 121: 109604.
[http://dx.doi.org/10.1016/j.biopha.2019.109604] [PMID: 31733570]
[59]
Mirsafaei L. Reiner ژ, Shafabakhsh R, Asemi Z. Molecular and biological functions of quercetin as a natural solution for cardiovascular disease prevention and treatment. Plant Foods Hum Nutr 2020; 75(3): 307-15.
[http://dx.doi.org/10.1007/s11130-020-00832-0] [PMID: 32588290]
[60]
Nettore IC, Rocca C, Mancino G, et al. Quercetin and its derivative Q2 modulate chromatin dynamics in adipogenesis and Q2 prevents obesity and metabolic disorders in rats. J Nutr Biochem 2019; 69: 151-62.
[http://dx.doi.org/10.1016/j.jnutbio.2019.03.019] [PMID: 31096072]
[61]
Piao S, Kang M, Lee YJ. Cytotoxic effects of escin on human castration-resistant prostate cancer cells through the induction of apoptosis and G2/M cell cycle arrest. Urology 2014; 84(4): 982.
[62]
Chan ST, Yang NC, Huang CS, Liao JW, Yeh SL. Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PLoS One 2013; 8(1): e54255.
[http://dx.doi.org/10.1371/journal.pone.0054255] [PMID: 23342112]
[63]
Kim GT, Lee SH, Kim J, Kim YM. Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway and induces apoptosis by increasing the generation of intracellular ROS in a p53-independent manner. Int J Mol Med 2014; 33(4): 863-9.
[http://dx.doi.org/10.3892/ijmm.2014.1658] [PMID: 24535669]
[64]
Chakraborty S, Stalin S, Das N, Choudhury S, Ghosh S, Swarnakar S. The use of nano-quercetin to arrest mitochondrial damage and MMP-9 upregulation during prevention of gastric inflammation induced by ethanol in rat. Biomaterials 2012; 33(10): 2991-3001.
[http://dx.doi.org/10.1016/j.biomaterials.2011.12.037] [PMID: 22257724]
[65]
Ahmad U, Ali A, Khan MM, et al. Nanotechnology-based strategies for nutraceuticals: A review of current research development. Nanoscie Technol. Int J 2019; 10(2): 35-44.
[http://dx.doi.org/10.1615/NanoSciTechnolIntJ.2019030098]
[66]
Alexander A. Ajazuddin, Patel RJ, Saraf S, Saraf S. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release 2016; 241: 110-24.
[http://dx.doi.org/10.1016/j.jconrel.2016.09.017] [PMID: 27663228]
[67]
Zhao J, Liu J, Wei T, et al. Quercetin-loaded nanomicelles to circumvent human castration-resistant prostate cancer in vitro and in vivo. Nanoscale 2016; 8(9): 5126-38.
[http://dx.doi.org/10.1039/C5NR08966B] [PMID: 26875690]
[68]
Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 2013; 8(3): 449-67.
[http://dx.doi.org/10.2217/nnm.13.8] [PMID: 23477336]
[69]
Svenson S. Clinical translation of nanomedicines. Curr Opin Solid State Mater Sci 2012; 16(6): 287-94.
[http://dx.doi.org/10.1016/j.cossms.2012.10.001]
[70]
Wei T, Chen C, Liu J, et al. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci 2015; 112(10): 2978-83.
[http://dx.doi.org/10.1073/pnas.1418494112] [PMID: 25713374]
[71]
Shitole AA, Sharma N, Giram P, et al. LHRH-conjugated, PEGylated, poly-lactide-co-glycolide nanocapsules for targeted delivery of combinational chemotherapeutic drugs Docetaxel and Quercetin for prostate cancer. Mater Sci Eng C 2020; 114: 111035.
[http://dx.doi.org/10.1016/j.msec.2020.111035] [PMID: 32994029]
[72]
Li M, Tang Z, Zhang Y, et al. LHRH-peptide conjugated dextran nanoparticles for targeted delivery of cisplatin to breast cancer. J Mater Chem B Mater Biol Med 2014; 2(22): 3490-9.
[http://dx.doi.org/10.1039/c4tb00077c] [PMID: 32261469]
[73]
Klippstein R, Wang JT, El‐Gogary RL, et al. Passively targeted curcumin‐loaded pegylated PLGA nanocapsules for colon cancer therapy in vivo. Small 2015; 11(36): 4704-22.
[http://dx.doi.org/10.1002/smll.201403799]
[74]
Mousavi N, Rahimi S, Emami H, Kazemi AH, Kashi R, Heidarian R. The effect of quercetin nanosuspension on prostate cancer cell line LNCaP via hedgehog signaling pathway. Rep Biochem Mol Biol 2021; 10(1): 69-75.
[http://dx.doi.org/10.52547/rbmb.10.1.69] [PMID: 34277870]
[75]
Cheng CK, Luo JY, Lau CW, Chen ZY, Tian XY, Huang Y. Pharmacological basis and new insights of resveratrol action in the cardiovascular system. Br J Pharmacol 2020; 177(6): 1258-77.
[http://dx.doi.org/10.1111/bph.14801] [PMID: 31347157]
[76]
Elshaer M, Chen Y, Wang XJ, Tang X. Resveratrol: An overview of its anti-cancer mechanisms. Life Sci 2018; 207: 340-9.
[http://dx.doi.org/10.1016/j.lfs.2018.06.028] [PMID: 29959028]
[77]
Fan Y, Li J, Yang Y, et al. Resveratrol modulates the apoptosis and autophagic death of human lung adenocarcinoma A549 cells via a p53 dependent pathway: Integrated bioinformatics analysis and experimental validation. Int J Oncol 2020; 57(4): 925-38.
[http://dx.doi.org/10.3892/ijo.2020.5107] [PMID: 32945383]
[78]
Dhar S, Hicks C, Levenson AS. Resveratrol and prostate cancer: Promising role for microRNAs. Mol Nutr Food Res 2011; 55(8): 1219-29.
[http://dx.doi.org/10.1002/mnfr.201100141] [PMID: 21714127]
[79]
Sinha D, Sarkar N, Biswas J, Bishayee A. Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. Semin Cancer Biol 2016; 40-41: 209-32.
[http://dx.doi.org/10.1016/j.semcancer.2015.11.001] [PMID: 26774195]
[80]
Lee KW, Bode AM, Dong Z. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 2011; 11(3): 211-8.
[http://dx.doi.org/10.1038/nrc3017] [PMID: 21326325]
[81]
Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J Nutr Biochem 2005; 16(8): 449-66.
[http://dx.doi.org/10.1016/j.jnutbio.2005.01.017] [PMID: 16043028]
[82]
Emília Juan M, Buenafuente J, Casals I, Planas JM. Plasmatic levels of trans-resveratrol in rats. Food Res Int 2002; 35(2-3): 195-9.
[http://dx.doi.org/10.1016/S0963-9969(01)00183-1]
[83]
Sanna V, Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Maturitas 2012; 73(1): 27-32.
[http://dx.doi.org/10.1016/j.maturitas.2012.01.016] [PMID: 22341739]
[84]
Nassir AM, Shahzad N, Ibrahim IAA, Ahmad I, Md S, Ain MR. Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells. Saudi Pharm J 2018; 26(6): 876-85.
[http://dx.doi.org/10.1016/j.jsps.2018.03.009] [PMID: 30202231]
[85]
Chaudhary Z, Subramaniam S, Khan GM, et al. Encapsulation and controlled release of resveratrol within functionalized mesoporous silica nanoparticles for prostate cancer therapy. Front Bioeng Biotechnol 2019; 7: 225.
[http://dx.doi.org/10.3389/fbioe.2019.00225] [PMID: 31620434]
[86]
Zhou Y, Quan G, Wu Q, et al. Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B 2018; 8(2): 165-77.
[http://dx.doi.org/10.1016/j.apsb.2018.01.007] [PMID: 29719777]
[87]
Zhang L, Lin Z, Chen Y, et al. Co-delivery of docetaxel and resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer. Eur J Pharm Sci 2022; 174: 106199.
[http://dx.doi.org/10.1016/j.ejps.2022.106199] [PMID: 35533965]
[88]
Harrington KJ, Rowlinson-Busza G, Uster PS, Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer Chemother Pharmacol 2000; 46(1): 10-8.
[http://dx.doi.org/10.1007/s002800000128] [PMID: 10912572]
[89]
Wenzel E, Somoza V. Metabolism and bioavailability oftrans-resveratrol. Mol Nutr Food Res 2005; 49(5): 472-81.
[http://dx.doi.org/10.1002/mnfr.200500010] [PMID: 15779070]
[90]
Yan J, Wang Y, Zhang X, Liu S, Tian C, Wang H. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv 2016; 23(5): 1757-62.
[http://dx.doi.org/10.3109/10717544.2015.1069423] [PMID: 26203689]
[91]
Azandeh SS, Abbaspour M, Khodadadi A, Khorsandi L, Orazizadeh M, Heidari-Moghadam A. Anticancer activity of curcuminv-loaded PLGA nanoparticles on PC3 prostate cancer cells. Iran J Pharm Res 2017; 16(3): 868-79.
[PMID: 29201078]
[92]
Hemati M, Haghiralsadat F, Yazdian F, Jafari F, Moradi A, Malekpour-Dehkordi Z. Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy. Artif Cells Nanomed Biotechnol 2019; 47(1): 1295-311.
[http://dx.doi.org/10.1080/21691401.2018.1489271] [PMID: 30033768]
[93]
Eroglu E. A Resveratrol-Loaded Poly(2-hydroxyethyl methacrylate)-Chitosan based nanotherapeutic: Characterization and in vitro cytotoxicity against prostate cancer. J Nanosci Nanotechnol 2021; 21(4): 2090-8.
[http://dx.doi.org/10.1166/jnn.2021.19317] [PMID: 33500023]
[94]
Sanna V, Siddiqui IA, Sechi M, Mukhtar H. Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(d, l -lactic- co -glycolic acid)–poly(ethylene glycol) blend for prostate cancer treatment. Mol Pharm 2013; 10(10): 3871-81.
[http://dx.doi.org/10.1021/mp400342f] [PMID: 23968375]
[95]
Wu YY, Xu YM, Lau ATY. Epigenetic effects of herbal medicine. Clin Epigenetics 2023; 15(1): 85.
[http://dx.doi.org/10.1186/s13148-023-01481-1] [PMID: 37179342]
[96]
Jang HL, Zhang YS, Khademhosseini A. Boosting clinical translation of nanomedicine. Nanomedicine 2016; 11(12): 1495-7.
[http://dx.doi.org/10.2217/nnm-2016-0133] [PMID: 27176482]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy